A new frontier in haematology - Combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 274-281

  Arpon, David Rey ^a,b   Gandhi, Maher K ^a,b,c   Martin, Jennifer H ^a,b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

haematology; imatinib; pharmacodynamics; pharmacokinetics; rituximab

Indexed keywords

IMATINIB; RITUXIMAB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BODY COMPOSITION; BODY WEIGHT; CANCER SURVIVAL; CLINICAL PHARMACOLOGY; COMORBIDITY; DNA POLYMORPHISM; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SEX DIFFERENCE; BIOLOGICAL MODEL; DECISION MAKING; DOSE RESPONSE; DRUG ADMINISTRATION; GENETICS; HEMATOLOGIC NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BENZAMIDES; DECISION MAKING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEMATOLOGIC NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PIPERAZINES; PYRIMIDINES; SEX FACTORS;

EID: 84904870914     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12318     Document Type: Article

References (55)

1. DeVita VT Jr, Chu E,. A history of cancer chemotherapy. Cancer Res 2008; 68: 8643-8653.
2. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, George SL, Pui CH,. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986; 314: 471-477.
3. Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C,. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007; 62: 43-52.
4. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Paab R, Newman RA, Hanna N, Anderson DR,. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
5. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Cevigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P,. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
6. Fanale MA, Younes A,. Monoclonal antibodies in the treatment of non-Hodgkins lymphoma. Drugs 2007; 67: 333-350.
7. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G,. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64: 4664-4669.
8. Cerny T, Borisch B, Introna M, Johnson P, Rose AL,. Mechanism of action of rituximab. Anticancer Drugs 2002; 13: (Suppl. 2): S3-10.
9. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Gisselbrecht C,. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
10. Pfreundschuh M, Trümper L, Österberg A, Pettengell R, Tmeny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lõpez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M,. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
11. Gandhi MK, Marcus RE,. Follicular lymphoma: time for a re-think? Blood Rev 2005; 19: 165-178.
12. Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilber O,. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009; 101: 248-255.
13. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S,. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
14. Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI,. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756-1765.
15. Stasi R, Adalberto P, Stipa E, Amadori S,. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-957.
16. Ng CM, Bruno R, Combs D, Davies B,. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45: 792-801.
17. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N,. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58-60.
18. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D,. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
19. Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, Morishima Y, Murate T, Kasai M, Uike N, Taniwaki M, Kano Y, Ohnishi K, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K,. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13: 928-943.
20. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ,. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-2170.
21. Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, Ohtsu T, Igarashi T, Sasaki Y, Kinoshita T, Murate T,. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998; 9: 527-534.
22. Cragg MS, Glennie MJ,. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738-2743.
23. Wada N, Aozasa K,. Loss of CD20 expression after rituximab therapy for B-cell lymphomas: a review of the literature. Cancer Clin Oncol 2012; 1: 1-10.
24. Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS,. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res 2012; 18: 1039-1050.
25. Dayde D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, Le Pape A, Bardos P, Paintaud G, Cartron G,. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009; 113: 3765-3772.
26. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E,. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008; 9: 435-444.
27. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H,. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758.
28. Ternant D, Cartron G, Hénin E, Tod M, Girard P, Paintaud G,. Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. Br J Clin Pharmacol 2012; 73: 597-605.
29. Li SC, Chen YC, Evens AM, Lee CC, Liao HF, Yu CC, Tung YT, Su YC,. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V/F) polymorphism. Am J Hematol 2010; 85: 810-812.
30. Cairoli R, Grillo G, Tedeschi A, D'Avanzo G, Marenco P, Morra E,. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 2004; 89: 361-363.
31. Keane C, Nourse JP, Crooks P, Nguyen-Van D, Mutsando H, Mollee P, Lea RA, Gandhi MK,. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Intern Med J 2012; 42: 1113-1119.
32. Müller C, Murawski N, Wiesen MHJ, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M,. The role of gender and weight on rituximab clearance and serum elimination half life in elderly patients with DLBCL. Blood 2012; 119: 3276-3284.
33. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF,. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44: 499-523.
34. Khamly KK, Thursield VJ, Fay M, Desai J, Toner GC, Choong PF, Ngan SY, Powell GJ, Thomas DM,. Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer 2009; 125: 426-431.
35. Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JG, Tang TC, Chang H, Hung YS,. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B-cell lymphoma. Ann Hematol 2012; 91: 1383-1391.
36. Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R,. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 2012; 97: 1431-1438.
37. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M, German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
38. Delarue R, Tilly H, Salles G, Gisselbrecht C, Mounier N, Fournier M, Molina TJ, Bonmati C, Ghesquieres H, Blanc M, Germain D, Girard L, Haioun C, Bosly A,. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA Study. Blood (ASH Annual Meeting Abstracts) 2009; 114: 169s [abstract 406].
39. Cunningham D, Smith P, Mouncey P, Qian W, Jack AS, Pocock C, Ardeshna K, Radford JA, Davies AJ, McMillan A, Linch MD,. CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol 2011; 29: 504s [abstract 8000].
40. Reiser M, Wenger M, Nickenig C, Peter N, Metzner B, Pfreundschuh M,. Serum levels and pharmacokinetic of rituximab in bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial. Blood (ASH Annual Meeting Abstracts) 2006; 108: 778a [abstract 2748].
41. Pfreundschuh M, Held G, Zeynalova S, Pöscher V, Viardot A, Hänel M, Keller U, Reiser M, Löffler M, Murawski N,. Improved outcome of elderly poor-prognosis DLBCL patients with 6xCHOP-14 and 8 applications of rituximab (R) given over an extended period: results of the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood (ASH Annual Meeting Abstracts) 2011; 118: 272-273 [abstract 592].
42. Saleem M, Dimeski G, Kirkpatrick CM, Taylor PJ, Martin JH,. Target concentration intervention in oncology: where are we at? Ther Drug Monit 2012; 34: 257-265.
43. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH,. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499-505.
44. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R,. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.
45. Joske DJ,. Chronic myeloid leukaemia: the evolution of gene-targeted therapy. Med J Aust 2008; 189: 277-282.
46. Weisberg E, Griffin JD,. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498-3505.
47. Corbin AS,. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611-4614.
48. Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K, Kohno A, Sugiura I, Yokozawa T, Hanamura A, Yamamoto K, Iida H, Emi N, Suzuki R, Ohnishi K, Naoe T,. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci 2010; 101: 2186-2192.
49. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y,. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022-4028.
50. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G,. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 2013; 98: 193-200.
51. Radich JP,. Chronic myeloid leukemia 2010: where are we now and where can we go? Hematology Am Soc Hematol Educ Program Book 2010; 2010: 122-128.
52. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW, Hughes TP,. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010; 28: 2761-2767.
53. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A,. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008; 14: 3141-3148.
54. Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, Qian SX,. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 2011; 28: 265-269.
55. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M, Mahon FX,. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008; 112: 2024-2027.